Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines.
The characteristic features of Alzheimer's disease (AD) include a high density of beta-amyloid-containing plaques in the cerebral cortex and the loss of basal forebrain cholinergic neurons. Amyloid beta-protein (A beta, Mr. approximately 4.5 kDa) is derived from a family of large (Mr. approximately 110-140 kDa) beta-amyloid precursor proteins (APP) which are integral membrane glycoproteins consisting of a large extracytoplasmic domain, a transmembrane domain, and a short cytoplasmic tail. Secreted derivatives of APP lacking the cytoplasmic tail, transmembrane domain, and a small portion of the extracellular domain are generated by the proteolytic processing of full length APP by a family of proteolytic enzymes known as APP secretases. Using cell cultures, we investigated the possibility that APP processing can be regulated by a centrally active cholinesterase inhibitor, tacrine, which has recently been shown to improve memory and cognitive functions in patients with AD. We analyzed the level of APP in glial, fibroblast, pheochromocytoma (PC12), and neuroblastoma cells by immunoblotting cell lysates and conditioned media. Normal levels of secretion of soluble APP derivatives by cells into conditioned media were severely inhibited by treating cells with tacrine. A similar decrease after treatment with tacrine was observed when neuroblastoma and PC12 cells were pretreated with either growth factors, phorbol ester, or retinoic acid. To determine whether the effect of tacrine on APP levels was specific or a more general phenomenon affecting other proteins, we measured the level of heat shock protein-70 (HSP-70) and another secretory protein, protease nexin-1 (PN-1). Tacrine treatment did not alter the level of HSP-70 in cell extracts and tacrine affected mildly the secretion of PN-1. Thus, the processing of HSP and PN-1, unlike APP, was not severely affected by treating cells with tacrine. Our results suggest that tacrine may inhibit an acetylcholinesterase-associated proteolytic activity involved in the secretion of APP, which results in less secretion of soluble APP into the conditioned media from tacrine treated cells. These results demonstrate that tacrine regulates APP secretion in cell cultures and suggest the possibility that tacrine therapy of Alzheimer's disease may, in the longer term, have effects on the process of A beta deposition.
Lahiri
D K
DK
Department of Psychiatry and Neurology, Indiana University School of Medicine, Indianapolis 46202-4887.
Lewis
S
S
Farlow
M R
MR
D016564:Amyloid beta-Protein Precursor / Q000096:biosynthesis*; D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D017077:Culture Media, Conditioned; D004591:Electrophoresis, Polyacrylamide Gel; D005910:Glioma / Q000378:metabolism; D006367:HeLa Cells; D006360:Heat-Shock Proteins / Q000096:biosynthesis; D006801:Humans; D015151:Immunoblotting; D007457:Iodine Radioisotopes; D009447:Neuroblastoma / Q000378:metabolism; D016716:PC12 Cells; D013619:Tacrine / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D016564:Amyloid beta-Protein Precursor; D002800:Cholinesterase Inhibitors; D017077:Culture Media, Conditioned; D006360:Heat-Shock Proteins; D007457:Iodine Radioisotopes; D013619:Tacrine